Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01524991 · ClinicalTrials.gov registry record · Phase 2
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
A Phase 2 study of Urothelial Carcinoma, sponsored by Hoosier Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 8
- Study locations
NCT01524991 is a Phase 2 study of Urothelial Carcinoma that has completed, run by Hoosier Cancer Research Network. The registered enrollment target is 36 participants, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT01524991, a Phase 2 study of Urothelial Carcinoma, has completed, sponsored by Hoosier Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 8
- Study locations
Study Summary
Gemcitabine plus cisplatin is standard treatment for advanced urothelial cancer. Ipilimumab has shown intriguing activity as neoadjuvant therapy in patients with clinically localized bladder cancer undergoing radical cystectomy. The combination of gemcitabine, cisplatin, plus ipilimumab may build on the chemosensitivity of urothelial carcinoma to produce more durable responses and improved outcomes.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Ipilimumab
- DRUG Gemcitabine
Study Locations (8)
Indiana
- IU Health Goshen Hospital - Goshen
- Indiana University Melvin & Bren Simon Cancer Center - Indianapolis
- IU Health Central Indiana Cancer Centers - Indianapolis
California
- City of Hope: Duarte - Duarte
Nebraska
- Nebraska Cancer Specialists - Omaha
New York
- Tisch Cancer Institute at Mount Sinai Medical Center - New York
Texas
- Texas Oncology, PA - Dallas
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-01 |
| Est. Completion | 2018-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01524991
The ClinicalTrials.gov registry entry for NCT01524991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is Hoosier Cancer Research Network, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT01524991 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Indiana, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT01524991 about?
NCT01524991 is a clinical study titled "First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma". Gemcitabine plus cisplatin is standard treatment for advanced urothelial cancer. Ipilimumab has shown intriguing activity as neoadjuvant therapy in patients with clinically localized bladder cancer undergoing radical cystectomy. The combination of gemcitabine, cisplatin, plus ipilimumab may build on...
What is the current status of trial NCT01524991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2012-01. Estimated completion is 2018-12-31.
What conditions does trial NCT01524991 study?
This clinical trial studies the following conditions: Urothelial Carcinoma.
What interventions are being tested in trial NCT01524991?
The interventions under investigation include: Cisplatin (DRUG), Ipilimumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01524991?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01524991 being conducted?
This trial has 8 study locations across California, Indiana, Nebraska, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Circulating Tumor DNA Response In Urothelial Cancer
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RECRUITING · Phase 2
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
RECRUITING · Phase 2
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.